

Weidong Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/481566/publications.pdf>

Version: 2024-02-01

147
papers

8,720
citations

44069

48
h-index

53230

85
g-index

154
all docs

154
docs citations

154
times ranked

12214
citing authors

#	ARTICLE	IF	CITATIONS
1	Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. <i>Science</i> , 2020, 368, .	12.6	716
2	LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. <i>Journal of Translational Medicine</i> , 2015, 13, 308.	4.4	469
3	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. <i>Cell Research</i> , 2020, 30, 966-979.	12.0	349
4	New development in CAR-T cell therapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 53.	17.0	282
5	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	17.0	256
6	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. <i>Science China Life Sciences</i> , 2016, 59, 468-479.	4.9	222
7	CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. <i>OncolImmunology</i> , 2018, 7, e1440169.	4.6	219
8	Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	212
9	lncRNAs: Insights into their function and mechanics in underlying disorders. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 762, 1-21.	5.5	196
10	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. <i>Protein and Cell</i> , 2018, 9, 838-847.	11.0	196
11	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 30.	17.0	187
12	Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. <i>Biomarker Research</i> , 2018, 6, 4.	6.8	184
13	Phase I Study of Chimeric Antigen Receptorâ€“Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1277-1286.	7.0	159
14	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. <i>Nature Cancer</i> , 2022, 3, 108-121.	13.2	150
15	Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. <i>OncolImmunology</i> , 2015, 4, e1027469.	4.6	142
16	Addition of Low-Dose Decitabine to Antiâ€“PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1479-1489.	1.6	135
17	Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. <i>Stem Cells</i> , 2016, 34, 627-639.	3.2	120
18	Target selection for CAR-T therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 62.	17.0	118

#	ARTICLE	IF	CITATIONS
19	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	1.8	115
20	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 33961-33971.	1.8	113
21	Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. <i>Science China Life Sciences</i> , 2016, 59, 1305-1312.	4.9	110
22	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. <i>Nature Communications</i> , 2021, 12, 409.	12.8	109
23	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 128.	17.0	106
24	The macro domain protein family: Structure, functions, and their potential therapeutic implications. <i>Mutation Research - Reviews in Mutation Research</i> , 2011, 727, 86-103.	5.5	104
25	Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. <i>Cancer Letters</i> , 2014, 354, 12-20.	7.2	98
26	Epithelial-mesenchymal transition: An emerging target in tissue fibrosis. <i>Experimental Biology and Medicine</i> , 2016, 241, 1-13.	2.4	95
27	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 134.	17.1	84
28	Mesenchymal stem cell therapy in type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 36.	2.7	82
29	Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. <i>Protein and Cell</i> , 2018, 9, 867-878.	11.0	81
30	Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. <i>Stem Cell Research and Therapy</i> , 2017, 8, 241.	5.5	80
31	Mesenchymal stem cell-conditioned medium accelerates wound healing with fewer scars. <i>International Wound Journal</i> , 2017, 14, 64-73.	2.9	77
32	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. <i>Cytotherapy</i> , 2020, 22, 573-580.	0.7	77
33	Substrate stiffness regulates B cell activation, proliferation, class switch, and T cell-independent antibody responses in vivo. <i>European Journal of Immunology</i> , 2015, 45, 1621-1634.	2.9	76
34	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	1.8	76
35	Hypoxia pretreatment of bone marrow-derived mesenchymal stem cells seeded in a collagen-chitosan sponge scaffold promotes skin wound healing in diabetic rats with hindlimb ischemia. <i>Wound Repair and Regeneration</i> , 2016, 24, 45-56.	3.0	74
36	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73

#	ARTICLE	IF	CITATIONS
37	Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. , 2020, 8, e000367.		72
38	Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. Journal of Translational Medicine, 2019, 17, 251.	4.4	71
39	Hypoxia Pretreatment of Bone Marrow Mesenchymal Stem Cells Facilitates Angiogenesis by Improving the Function of Endothelial Cells in Diabetic Rats with Lower Ischemia. PLoS ONE, 2015, 10, e0126715.	2.5	70
40	Treatment of MSCs with Wnt1a-conditioned medium activates DP cells and promotes hair follicle regrowth. Scientific Reports, 2014, 4, 5432.	3.3	64
41	Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2016, 9, 131.	17.0	60
42	Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. Cell Death and Disease, 2018, 9, 760.	6.3	60
43	Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. Human Molecular Genetics, 2014, 23, 6008-6021.	2.9	59
44	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein and Cell, 2017, 8, 896-925.	11.0	59
45	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	10.5	57
46	Mesenchymal Stem Cellâ€“Conditioned Medium Improves the Proliferation and Migration of Keratinocytes in a Diabetes-Like Microenvironment. International Journal of Lower Extremity Wounds, 2015, 14, 73-86.	1.1	55
47	Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting <i>ABCF1</i>. Current Protein and Peptide Science, 2015, 16, 301-309.	1.4	55
48	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein and Cell, 2017, 8, 861-877.	11.0	53
49	Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report. Journal of Immunology Research, 2014, 2014, 1-14.	2.2	52
50	Macroscopic Supramolecular Assembly to Fabricate 3D Ordered Structures: Towards Potential Tissue Scaffolds with Targeted Modification. Advanced Functional Materials, 2015, 25, 6851-6857.	14.9	51
51	Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chinese Journal of Cancer, 2015, 34, 99-107.	4.9	51
52	Clinical development of CAR T cell therapy in China: 2020 update. Cellular and Molecular Immunology, 2021, 18, 792-804.	10.5	50
53	Hypoxia Regulates the Therapeutic Potential of Mesenchymal Stem Cells Through Enhanced Autophagy. International Journal of Lower Extremity Wounds, 2015, 14, 63-72.	1.1	48
54	Effect of Mst1 on Endometriosis Apoptosis and Migration: Role of Drp1-Related Mitochondrial Fission and Parkin-Required Mitophagy. Cellular Physiology and Biochemistry, 2018, 45, 1172-1190.	1.6	46

#	ARTICLE	IF	CITATIONS
55	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. <i>Protein and Cell</i> , 2018, 9, 516-526.	11.0	46
56	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2019, 12, 57.	17.0	46
57	The Accomplices of NF- κ B Lead to Radioresistance. <i>Current Protein and Peptide Science</i> , 2015, 16, 279-294.	1.4	46
58	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1 trial. <i>Leukemia</i> , 2022, 36, 189-196.	7.2	45
59	A Conditioned Medium of Umbilical Cord Mesenchymal Stem Cells Overexpressing Wnt7a Promotes Wound Repair and Regeneration of Hair Follicles in Mice. <i>Stem Cells International</i> , 2017, 2017, 1-13.	2.5	43
60	Mesenchymal stem cells ameliorate myocardial fibrosis in diabetic cardiomyopathy via the secretion of prostaglandin E2. <i>Stem Cell Research and Therapy</i> , 2020, 11, 122.	5.5	43
61	Increased IFN γ + T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6031-6043.	7.0	42
62	Mesenchymal stem cell-based therapy for nonhealing wounds: today and tomorrow. <i>Wound Repair and Regeneration</i> , 2015, 23, 465-482.	3.0	39
63	Insight into Reepithelialization: How Do Mesenchymal Stem Cells Perform?. <i>Stem Cells International</i> , 2016, 2016, 1-9.	2.5	39
64	Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor. <i>Frontiers in Oncology</i> , 2019, 9, 1196.	2.8	39
65	Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. <i>Journal of Pathology</i> , 2015, 236, 165-174.	4.5	37
66	The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice. <i>International Immunopharmacology</i> , 2018, 60, 235-245.	3.8	37
67	Culturing on Wharton's Jelly Extract Delays Mesenchymal Stem Cell Senescence through p53 and p16INK4a/pRb Pathways. <i>PLoS ONE</i> , 2013, 8, e58314.	2.5	36
68	An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 16698-16711.	1.8	36
69	Standardizing CAR-T therapy: Getting it scaled up. <i>Biotechnology Advances</i> , 2019, 37, 239-245.	11.7	35
70	Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. , 2021, 9, e002347.		35
71	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	2.2	32
72	LRP16 Integrates into NF- κ B Transcriptional Complex and Is Required for Its Functional Activation. <i>PLoS ONE</i> , 2011, 6, e18157.	2.5	32

#	ARTICLE	IF	CITATIONS
73	DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. <i>Journal of Genetics and Genomics</i> , 2018, 45, 205-214.	3.9	30
74	Granulocyte-Colony Stimulating Factor (G-CSF) Accelerates Wound Healing in Hemorrhagic Shock Rats by Enhancing Angiogenesis and Attenuating Apoptosis. <i>Medical Science Monitor</i> , 2017, 23, 2644-2653.	1.1	30
75	Identification of global transcriptome abnormalities and potential biomarkers in eutopic endometria of women with endometriosis: A preliminary study. <i>Biomedical Reports</i> , 2017, 6, 654-662.	2.0	29
76	Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. <i>Journal of Genetics and Genomics</i> , 2019, 46, 367-377.	3.9	29
77	The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. <i>Oncotarget</i> , 2018, 9, 2105-2119.	1.8	29
78	Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth. <i>Oncotarget</i> , 2015, 6, 22126-22138.	1.8	29
79	Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 575-586.	7.0	28
80	Umbilical cord-derived mesenchymal stromal cell-conditioned medium exerts in vitro antiaging effects in human fibroblasts. <i>Cytotherapy</i> , 2017, 19, 371-383.	0.7	26
81	Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 430-432.	10.5	26
82	Beta-cell regeneration from vimentin+/MafB+ cells after STZ-induced extreme beta-cell ablation. <i>Scientific Reports</i> , 2015, 5, 11703.	3.3	25
83	Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice. <i>Stem Cell Research and Therapy</i> , 2019, 10, 259.	5.5	25
84	Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1671.	2.8	25
85	Wnt1a maintains characteristics of dermal papilla cells that induce mouse hair regeneration in a 3D preculture system. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 1479-1489.	2.7	24
86	Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway. <i>Oncolmmunology</i> , 2020, 9, 1824643.	4.6	24
87	The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. <i>Oncolmmunology</i> , 2017, 6, e1323619.	4.6	23
88	Preferred M2 Polarization by ASC-Based Hydrogel Accelerated Angiogenesis and Myogenesis in Volumetric Muscle Loss Rats. <i>Stem Cells International</i> , 2017, 2017, 1-13.	2.5	23
89	DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. <i>Oncotarget</i> , 2016, 7, 37882-37892.	1.8	22
90	Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 106.	17.0	22

#	ARTICLE	IF	CITATIONS
91	Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. <i>International Journal of Cancer</i> , 2018, 143, 1530-1540.	5.1	21
92	Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 541330.	2.8	21
93	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 2782-2791.	7.0	21
94	CD58 loss in tumor cells confers functional impairment of CAR T cells. <i>Blood Advances</i> , 2022, 6, 5844-5856.	5.2	20
95	FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells. <i>Nucleic Acids Research</i> , 2009, 37, 3996-4009.	14.5	19
96	An LRP16-containing preassembly complex contributes to NF- κ B activation induced by DNA double-strand breaks. <i>Nucleic Acids Research</i> , 2015, 43, 3167-3179.	14.5	19
97	Exploring innate immunity in cancer immunotherapy: opportunities and challenges. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1607-1609.	10.5	19
98	Blockade of the LRP16-PKR-NF- κ B signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy. <i>ELife</i> , 2017, 6, .	6.0	19
99	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	17.1	19
100	The Effect of Adipose-Derived Stem Cells on Full-Thickness Skin Grafts. <i>BioMed Research International</i> , 2016, 2016, 1-10.	1.9	16
101	Association between oestrogen receptor alpha (ESR1) gene polymorphisms and endometriosis: a meta-analysis of 24 case-control studies. <i>Reproductive BioMedicine Online</i> , 2016, 33, 335-349.	2.4	15
102	The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1019-1029.	1.7	15
103	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4521-4530.	7.0	15
104	Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. <i>European Journal of Immunology</i> , 2021, 51, 2513-2521.	2.9	15
105	Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance. <i>Current Protein and Peptide Science</i> , 2015, 16, 270-278.	1.4	15
106	Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study. <i>Current Protein and Peptide Science</i> , 2015, 16, 329-336.	1.4	15
107	Transdifferentiation of Umbilical Cord-Derived Mesenchymal Stem Cells Into Epidermal-Like Cells by the Mimicking Skin Microenvironment. <i>International Journal of Lower Extremity Wounds</i> , 2015, 14, 136-145.	1.1	14
108	An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. <i>Science China Life Sciences</i> , 2016, 59, 379-385.	4.9	14

#	ARTICLE	IF	CITATIONS
109	Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1431-1439.	2.5	14
110	M2 macrophages infusion ameliorates obesity and insulin resistance by remodeling inflammatory/macrophages' homeostasis in obese mice. <i>Molecular and Cellular Endocrinology</i> , 2017, 443, 63-71.	3.2	14
111	Spleen-Derived Anti-Inflammatory Cytokine IL-10 Stimulated by Adipose Tissue-Derived Stem Cells Protects Against Type 2 Diabetes. <i>Stem Cells and Development</i> , 2017, 26, 1749-1758.	2.1	14
112	Infusion of adipose-derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats. <i>Molecular Medicine Reports</i> , 2018, 17, 8466-8474.	2.4	14
113	Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. <i>Cancer Communications</i> , 2022, 42, 493-516.	9.2	14
114	Adaptive T cell immunotherapy in cancer. <i>Science China Life Sciences</i> , 2021, 64, 363-371.	4.9	13
115	Theoretical and practical aspects of using fetal fibroblasts for skin regeneration. <i>Ageing Research Reviews</i> , 2017, 36, 32-41.	10.9	11
116	Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1320-1332.	4.9	11
117	CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. <i>Blood Advances</i> , 2022, 6, 2695-2699.	5.2	11
118	Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. <i>Science China Life Sciences</i> , 2016, 59, 349-359.	4.9	10
119	Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. <i>Frontiers of Medicine</i> , 2020, 14, 726-745.	3.4	9
120	Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3038-3038.	1.6	8
121	Inducing immunogenic cell death in immuno-oncological therapies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 1-10.	2.2	8
122	Endometriosis research using capture microdissection techniques: Progress and future applications. <i>Biomedical Reports</i> , 2016, 5, 531-540.	2.0	7
123	Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1601-1610.	1.8	7
124	Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092760.	3.2	7
125	Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. <i>Theranostics</i> , 2021, 11, 4699-4709.	10.0	7
126	G-CSF Administration after the Intraosseous Infusion of Hypertonic Hydroxyethyl Starches Accelerating Wound Healing Combined with Hemorrhagic Shock. <i>BioMed Research International</i> , 2016, 2016, 1-9.	1.9	6

#	ARTICLE	IF	CITATIONS
127	CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies.. Journal of Clinical Oncology, 2017, 35, 3042-3042.	1.6	6
128	Acclimatized Induction Reveals the Multipotency of Adult Human Undifferentiated Keratinocytes. Cellular Reprogramming, 2010, 12, 283-294.	0.9	5
129	Mild hyperglycemia triggered islet function recovery in streptozotocin-induced insulin-deficient diabetic rats. Journal of Diabetes Investigation, 2017, 8, 44-55.	2.4	4
130	Extracellular Signal-Regulated Kinase 5 is Required for Low-Concentration H2O2-Induced Angiogenesis of Human Umbilical Vein Endothelial Cells. BioMed Research International, 2017, 2017, 1-13.	1.9	4
131	Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN- γ + CD4+ T Cells Through Enhancing I κ B α Degradation and NF- κ B Activation. Frontiers in Cell and Developmental Biology, 2021, 9, 647713.	3.7	4
132	DNA damage stress induces the dissociation of Smurf1/2 from MDM2 in a slow manner. Science Bulletin, 2011, 56, 3155.	1.7	3
133	Spotlight on decitabine for myelodysplastic syndromes in Chinese patients. OncoTargets and Therapy, 2015, 8, 2783.	2.0	3
134	A negative-feedback function of PKC δ in the formation and accumulation of signaling-active B cell receptor microclusters within B cell immunological synapse. Journal of Leukocyte Biology, 2015, 97, 887-900.	3.3	3
135	CART trials are going ahead. Science China Life Sciences, 2017, 60, 1276-1279.	4.9	3
136	The Role of Posttranslational Modifications in DNA Repair. BioMed Research International, 2020, 2020, 1-13.	1.9	3
137	Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma. PeerJ, 2020, 8, e9362.	2.0	3
138	Safety and efficacy of chidamide in combination with decitabine plus anti-PD-1 camrelizumab after relapse or progression on decitabine-plus-camrelizumab in classical Hodgkin lymphoma.. Journal of Clinical Oncology, 2021, 39, e19515-e19515.	1.6	2
139	Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.. Journal of Clinical Oncology, 2018, 36, 7537-7537.	1.6	2
140	Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies.. Journal of Clinical Oncology, 2017, 35, e14555-e14555.	1.6	2
141	Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital. Science China Life Sciences, 2016, 59, 1063-1067.	4.9	1
142	Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats. Stem Cells and Development, 2021, 30, 502-514.	2.1	1
143	Combined regimen of inhalable STING agonist plus chemoimmunotherapy in platinum-resistant or platinum-refractory ovarian cancer: A randomized, open-label, phase II trial.. Journal of Clinical Oncology, 2020, 38, 6071-6071.	1.6	1
144	The macrodomain family: Rethinking an ancient domain from evolutionary perspectives. Science Bulletin, 2013, 58, 953-960.	1.7	0

#	ARTICLE	IF	CITATIONS
145	A retrospective study of efficacy and safety of mechlorethamine, vindesine, liposomal doxorubicin, and prednisone (MODP) in relapsed/refractory classical Hodgkin lymphoma.. Journal of Clinical Oncology, 2021, 39, e19516-e19516.	1.6	0
146	Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cellular and Molecular Immunology, 2022, 19, 122-124.	10.5	0
147	769—CAR T cells undergoing epigenetic reprogramming by low-dose decitabine enhances persistent anti-tumor efficacy in vivo. , 2020, , .		0